Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1).

Published on Jun 16, 2020in Molecular Pharmaceutics4.321
· DOI :10.1021/ACS.MOLPHARMACEUT.0C00419
Mateusz Adam Krzyscik4
Estimated H-index: 4
Malgorzata Zakrzewska17
Estimated H-index: 17
Jacek Otlewski44
Estimated H-index: 44
In spite of significant progress in the field of targeted anticancer therapy, the FDA has approved only five ADC-based drugs. Hence the search for new targeted anticancer agents is an unfulfilled n...
📖 Papers frequently viewed together
13 Citations
1 Author (Maya S)
16 Citations
#1Sung Bae Kim (UOU: University of Ulsan)H-Index: 1
#2Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 108
Last. Jordan Berlin (VUMC: Vanderbilt University Medical Center)H-Index: 67
view all 12 authors...
Background Fibroblast growth factor receptor (FGFR) 2 is overexpressed in several tumor types, including triple-negative breast cancer and gastric cancer, both of which have a high unmet medical need. Aprutumab ixadotin (BAY 1187982) is the first antibody–drug conjugate (ADC) to target FGFR2 and the first to use a novel auristatin-based payload.
7 CitationsSource
ABSTRACT Antibody-drug conjugates (ADCs) are a promising therapeutic modality for oncology indications. The concept of an ADC platform is to increase the therapeutic index (TI) of chemotherapeutics through more selective delivery of cytotoxic agents to tumor cells while limiting exposure to healthy normal cells. Despite the use of antibodies targeting antigens abundantly and/or exclusively expressed on cancer cells (i.e., target cells), dose limiting toxicities (DLTs) in normal cells/tissues are...
15 CitationsSource
#1Brian C. MacknessH-Index: 4
#2Julie A. JaworskiH-Index: 4
Last. Huawei QiuH-Index: 10
view all 12 authors...
ABSTRACTThe neonatal Fc receptor (FcRn) promotes antibody recycling through rescue from normal lysosomal degradation. The binding interaction is pH-dependent with high affinity at low pH, but not u...
14 CitationsSource
#1Yingqin Hou (PKU: Peking University)H-Index: 10
#2Hua Lu (PKU: Peking University)H-Index: 25
Various polymers have been tested for protein conjugation with a goal of bridging the complementary advantages of both components. However, many of these polymers, including the most well-established PEG, are nondegradable, which raises potential concerns on their cumulative chronic toxicity. Moreover, the immunogenicity of PEG has recently evoked considerable controversy. Synthetic polypeptides, on the other hand, are biomimetic polymers with tunable degradability, versatile side chain function...
17 CitationsSource
#1Haichao Tang (PRC: China Medical University (PRC))H-Index: 2
#2Yan Liu (Shenyang)H-Index: 1
Last. Ying Jin (Shenyang)H-Index: 1
view all 9 authors...
Antibody-drug conjugates (ADCs) are developing rapidly in recent decades. However, it is complicated to map out a perfect ADC that requires optimization of multiple parameters including antigens, antibodies, linkers, payloads, and the payload-linker linkage. The therapeutic targets of the ADCs are expected to express only on the surface of the corresponding target tumor cells. On the contrary, many antigens usually express on normal tissues to some extent, which could disturb the specificity of ...
9 CitationsSource
#1Iriny Ekladious (BU: Boston University)H-Index: 6
#2Yolonda L. Colson (Brigham and Women's Hospital)H-Index: 51
Last. Mark W. Grinstaff (BU: Boston University)H-Index: 79
view all 3 authors...
Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several conjugates successfully translated into clinical practice. The conjugation of therapeutic agents to polymeric carriers, such as polyethylene glycol, offers several advantages, including improved drug solubilization, prolonged circulation, reduced immunogenicity, controlled release and enhanced safety. In this Review, we discuss the rational design, physicochemical characteristics and recent advances in the...
170 CitationsSource
#1Filip S. EkholmH-Index: 11
Last. Susanne K. WiedmerH-Index: 29
view all 9 authors...
Antibody-drug conjugates (ADCs) are promising state-of-the-art biopharmaceutical drugs for selective drug-delivery applications and the treatment of diseases such as cancer. The idea behind the ADC technology is remarkable as it combines the highly selective targeting capacity of monoclonal antibodies with the cancer-killing ability of potent cytotoxic agents. The continuous development of improved ADCs requires systematic studies on the nature and effects of warhead modification. Recently, we f...
4 CitationsSource
#1Natalia Porębska (UWr: University of Wrocław)H-Index: 3
#2Marta Latko (UWr: University of Wrocław)H-Index: 3
Last. Łukasz Opaliński (UWr: University of Wrocław)H-Index: 7
view all 6 authors...
Fibroblast growth factor receptors (FGFRs) in response to fibroblast growth factors (FGFs) transmit signals across the cell membrane, regulating important cellular processes, like differentiation, division, motility, and death. The aberrant activity of FGFRs is often observed in various diseases, especially in cancer. The uncontrolled FGFRs’ function may result from their overproduction, activating mutations, or generation of FGFRs’ fusion proteins. Besides their typical subcellular localization...
31 CitationsSource
#1Mohamed Altai (Uppsala University)H-Index: 19
#2Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 8 authors...
Abstract Patients with HER2-positive tumors often suffer resistance to therapy, warranting development of novel treatment modalities. Affibody molecules are small affinity proteins which can be engineered to bind to desired targets. They have in recent years been found to allow precise targeting of cancer specific molecular signatures such as the HER2 receptor. In this study, we have investigated the potential of an affibody molecule targeting HER2, ZHER2:2891, conjugated with the cytotoxic mayt...
17 CitationsSource
#1Alan J. RussellH-Index: 72
#2Stefanie L. Baker (CMU: Carnegie Mellon University)H-Index: 10
Last. Brent S. Sumerlin (UF: University of Florida)H-Index: 74
view all 8 authors...
19 CitationsSource
Cited By2
A single primary cilium projects from most vertebrate cells to guide cell fate decisions. A growing list of signaling molecules is found to function through cilia and control ciliogenesis, including the fibroblast growth factor receptors (FGFR). Aberrant FGFR activity produces abnormal cilia with deregulated signaling, which contributes to pathogenesis of the FGFR-mediated genetic disorders. FGFR lesions are also found in cancer, raising a possibility of cilia involvement in the neoplastic trans...
#1Marta Poźniak (UWr: University of Wrocław)
#2Natalia Porębska (UWr: University of Wrocław)H-Index: 3
Last. Łukasz Opaliński (UWr: University of Wrocław)H-Index: 7
view all 10 authors...
BACKGROUND Antibody drug conjugates (ADCs) represent one of the most promising approaches in the current immuno-oncology research. The precise delivery of cytotoxic drugs to the cancer cells using ADCs specific for tumor-associated antigens enables sparing the healthy cells and thereby reduces unwanted side effects. Overexpression of fibroblast growth factor receptor 1 (FGFR1) has been demonstrated in numerous tumors and thereby constitutes a convenient molecular target for selective cancer trea...
#1Mahendra Deonarain (Imperial College London)H-Index: 19
#2Gokhan Yahioglu (Imperial College London)H-Index: 24
Introduction: Antibody-Drug Conjugates (ADCs) have undergone a recent resurgence with 5 product approvals over the last 2 years but for those close to the field, it’s been repeated cycles of setbac...
3 CitationsSource